Plasma N-Cleaved Galectin-9 Is a Surrogate Marker for Determining the Severity of COVID-19 and Monitoring the Therapeutic Effects of Tocilizumab

Plasma N-Cleaved Galectin-9 Is a Surrogate Marker for Determining the Severity of COVID-19 and Monitoring the Therapeutic Effects of Tocilizumab

Galectin-9 (Gal-9) is known to contribute to antiviral responses in coronavirus disease 2019 (COVID-19). Increased circulating Gal-9 in COVID-19 is associated with COVID-19 severity. In a while, the linker-peptide of Gal-9 is susceptible to proteolysis that can cause the change or loss of Gal-9 acti...

Full description

Bibliographic Details
Main Authors: Hiroko Iwasaki-Hozumi, Yosuke Maeda, Toshiro Niki, Haorile Chagan-Yasutan, Gaowa Bai, Takashi Matsuba, Daisuke Furushima, Yugo Ashino, Toshio Hattori
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:International Journal of Molecular Sciences
Subjects:
coronavirus disease 2019
N-cleaved-Gal9
surrogate marker
proteolysis
severity
therapeutic effects
Online Access:https://www.mdpi.com/1422-0067/24/4/3591

Internet

https://www.mdpi.com/1422-0067/24/4/3591

Similar Items